Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 105,148

Document Document Title
WO/2024/001457A1
Provided is an extraction method for a milk-derived exosome, which successively carries out the following steps: (1) dividing milk raw materials, centrifuging same, and collecting a clear liquid; (2) centrifuging the clear liquid obtaine...  
WO/2024/004921A1
The present invention addresses the problem of providing a modified oxygenase capable of epoxidating specifically only the position-ω3 in a highly unsaturated fatty acid. The present invention relates to: a polypeptide comprising an ami...  
WO/2024/006955A1
The present disclosure relates to T cells engineered to comprise a heterologous nucleic acid sequence encoding a dual mutant transforming growth factor beta 1 (dmTGFB1) under control of a promoter sequence. In certain embodiments, the ce...  
WO/2024/001530A1
Disclosed are use of a combination of an activated T cell and a blocking antibody in the preparation of an anti-tumor medicament, and the anti-tumor medicament. The activated T cell is obtained by: separating T cells from the tissue or b...  
WO/2024/006361A1
The technology relates in part to compositions that include oligonucleotide probes useful for enriching nucleic acid preparation products for analysis, kits and related methods. Described herein are compositions comprising: a plurality o...  
WO/2024/006388A1
This invention provides vectors (e.g., lentiviral vectors) and expression cassettes for incorporation into vectors for expressing an alpha-globin (α-globin) gene. In certain embodiments method of treatment using such vectors are provided.  
WO/2024/005714A1
The present invention generally relates to the provision of a conditioned medium comprising magnetically-induced cell secretome, the methods of producing the same, and a system for 5 the production of said conditioned medium. More partic...  
WO/2024/004960A1
The present invention addresses the problem of providing a method that enables sufficient proliferation of cells, in particular immune competent cells, even in a serum-free medium or a low-serum medium, and a medium additive and a medium...  
WO/2024/003200A1
The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-a...  
WO/2024/000637A1
Provided is a combined pharmaceutical composition for treating a tumor, comprising a CAR-T cell and G-CSF. Also provided is use of the composition in the preparation of a drug for treating a tumor. The combination can significantly impro...  
WO/2024/003349A1
The present invention relates to a method for directing differentiation of ventral midbrain NSCs into neurons comprising contacting a cell population comprising ventral midbrain NSCs with an inhibitor of MEK signaling and an inhibitor of...  
WO/2024/006561A1
A method of producing human astrocytes from neural stem cells (NSCs) involves providing induced progenitor cells (iPSCs), differentiating iPSCs to neural stem cells (NSCs), and differentiating NSCs to astrocytes.  
WO/2024/001509A1
Provided are a niraparib-resistant human ovarian cancer cell line and use thereof. An A2780-NiraR (CCTCC Accession NO: C202299) drug-resistant cell line is established with human ovarian cancer A2780 cell line as the parent cell by gradu...  
WO/2024/005204A1
Provided is a novel protein, or the like, as a trispecific tribody in which antitumor effects have been augmented. The present invention relates to a fusion protein comprising a first chain and a second chain which are different from one...  
WO/2024/002129A1
A novel coronavirus heterologous trimerized chimeric antigen peptide, a polynucleotide encoding same or a nucleic acid product related to the polynucleotide, a vaccine or an immunogenic composition based on the antigen peptide or the pol...  
WO/2024/006928A2
The present disclosure provides editable cell lines, including the use of gene editing proteins to produce the cell lines. The editable cell lines are able to express antibody constant regions that can serve as a platform for the antibod...  
WO/2024/006391A1
Methods and compositions using novel menin-MLL inhibitors enhancing proliferation of pancreatic beta cells to increase the efficacy of cell-based therapeutics are disclosed. Also provided are cell-based therapy methods and compositions.  
WO/2024/001845A1
The present invention provides a preparation method and use of a defective filovirus. Specifically, the present invention provides a defective recombinant filovirus, a coding sequence of one or more key viral proteins in a genome of the ...  
WO/2023/249904A1
Provided herein are compositions and methods for treating diabetes (e.g., Type I diabetes and insulin dependent type II diabetes). In particular, provided herein are insulin secreting cells and uses thereof in the treatment of diabetes i...  
WO/2023/249396A1
The present invention provides: a method for preparing macrophages derived from induced pluripotent stem cells; and macrophages derived from induced pluripotent stem cells, prepared by the preparation method, the method comprising the st...  
WO/2023/246623A1
The present invention relates to a novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated C...  
WO/2023/245812A1
A cell sheet clamping device, a use method, and a preparation method for a neurorestorative material. The cell sheet clamping device comprises a frame, a fixed plate being fixedly arranged on the frame. A first clamping member is adjusta...  
WO/2023/246109A1
Provided are a cell strain for treating melanoma, and a multi-titer whole-cell vaccine prepared therefrom and a use method. The multi-titer whole-cell vaccine is prepared by means of mixing a ZJMM-45 homologous human melanoma cell strain...  
WO/2023/248362A1
[Problem] To provide a marker (indicator) for confirming a culture supernatant of dental pulp stem cells (SHED), of which a therapeutic effect such as cell regeneration is recognized. [Solution] miR-199b-5p and miR-130a-3p, which positiv...  
WO/2023/250336A1
Provided herein, inter alia, are compositions and methods including T-cell cultures enriched for gdT cells, the gdT cells expressing a CAR, and related methods for generating said cells. In an aspect provided herein is a method for gener...  
WO/2023/246885A1
The present disclosure relates to an antigen-binding molecule specifically binding to DLL3 and CD3, and pharmaceutical use thereof. The antigen-binding molecule can be used for treating cancers.  
WO/2023/247722A1
The present invention refers to An in vitro method of isolating hemogenic endothelial cells (HECs) or enriched populations of HECs, comprising isolating CD32+ cells from a population of cells derived from pluripotent stem cells.  
WO/2023/245609A1
Provided is a method for producing mature dendritic cells from peripheral blood mononuclear cells (PBMCs). The method includes the steps of treating the PBMCs with a cultivating medium supplemented with interleukin 4 (IL-4) and granulocy...  
WO/2023/249071A1
[Problem] To provide a novel T-cell receptor (TCR) which specifically recognizes glypican 3 (GPC3). [Solution] Provided is a T-cell receptor (TCR) that includes one amino acid sequence selected from the group consisting of the amino acid...  
WO/2023/249934A1
Provided are methods of genetically modifying cells. In certain embodiments, the methods comprise modifying a coding region of a mitochondrial gene of the cell. According to some embodiments, the modification results in increased transla...  
WO/2023/246012A1
Provided is a method for separating and extracting multiple subpopulations of gastric cancer tissue-derived extracellular vesicles, comprising: firstly immersing a tumor tissue into a digestive juice for enzymolysis digestion to obtain a...  
WO/2023/246911A1
The present invention relates to a T cell receptor-based bispecific polypeptide molecule and use thereof. The present invention further provides a nucleic acid encoding the polypeptide molecule of the present invention, a vector or a vec...  
WO/2023/246820A1
Provided are a compound for inducing a stem cell-like memory cell in vitro, and an application thereof. The compound is as shown in the following formula (I) or (II), and has glycogen synthase kinase 3 inhibitory activity. After combined...  
WO/2023/249104A1
The present invention addresses the problem of providing a system for, when producing a single type of cellular product using at least two types of tissue derived from the same patient, ultimately providing said single type of cellular p...  
WO/2023/246626A1
Provided are a cell with targeted integration, a method for preparing same, and a method for producing a target gene expression product. The cell with targeted integration comprises a nucleic acid fragment set forth in SEQ ID NO. 1 compr...  
WO/2023/245283A1
There is described herein methods of ameliorating, treating or preventing graft-versus- host disease, transplant rejection or an autoimmune disorder, or promoting transplant graft function in a human using innate lymphoid cells (ILCs), i...  
WO/2023/246325A1
Disclosed are a nanobody (Nb) targeting CD73, a nanobody-drug conjugate (NDC), a preparation method therefor and use thereof. The monoclonal nanobody and the corresponding NDC of the present invention can efficiently and specifically bin...  
WO/2023/247324A1
The present invention relates to a combination of adoptively transferred cells (adoptive cells) and at least one anti-PDL1/PD1 antibody, wherein the adoptive cells comprises natural killer (NK) lymphocytes and T lymphocytes obtained by a...  
WO/2023/248934A1
A method for producing a cell support composite 10 includes: culturing renal cells in an aggregated state; separating the aggregates into individual cultured cells 16; seeding the cultured cells 16 onto a substrate 12 at a seeding densit...  
WO/2023/247733A1
The present disclosure provides a process for producing recombinant viral vectors in eukaryotic cells. In particular, the present disclosure relates to a process for the transient transfection of eukaryotic cells for production of recomb...  
WO/2023/246247A1
The present invention relates to a pharmaceutical composition, comprising an anti-CD73 (for example, human CD73) antibody or an antigen-binding fragment thereof, and an anti-PD-1-anti-VEGFA bispecific antibody or an antigen-binding fragm...  
WO/2023/249963A1
Application of adeno-associated virus (AAV) vectors in large animal studies and clinical trials often requires high-titer and high-potency vectors manufactured at a scale that can support large doses and/or large populations. A number of...  
WO/2023/246003A1
Provided are a chimeric antigen receptor macrophage, a method for preparing same, and use thereof. The chimeric antigen receptor macrophage is a mouse bone marrow-derived macrophage comprising a chimeric antigen receptor modification and...  
WO/2023/246642A1
Disclosed are a composition for treating spinal cord injury, a preparation method therefor and a use thereof. The composition comprises induced neural stem cells, fibrin and thrombin, and is particularly applicable for fully injured and ...  
WO/2023/246644A1
The present invention provides a spinal progenitor cell for treating amyotrophic lateral sclerosis (ALS). The spinal progenitor cell is represented as at least any two of PAX6+, SOX1+, Nkx6.1+, SOX2+, DBX2+, OLIG2+, PAX3+, or Nkx2.2+, an...  
WO/2023/246004A1
Disclosed are a chimeric antigen receptor, a macrophage expressing same, and use. A primary protein structure of the chimeric antigen receptor comprises sequentially from the amino terminus to the carboxyl terminus: a signal peptide, an ...  
WO/2023/246908A1
Provided are preparation and use of a chimeric antigen receptor immune cell targeting CSF1R. Specifically, provided is a chimeric antigen receptor (CAR) modified on the basis of a natural CSF1R ligand, the CAR comprising an extracellular...  
WO/2023/247532A1
Cardiovascular diseases represent the leading cause of mortality and accounts for approximately one-third of deaths globally each year. During the last decade, tremendous efforts have been made to take advantage of advances in regenerati...  
WO/2023/246578A1
A chimeric antigen receptor specifically binding to GPC3, a modified immune cell expressing the chimeric antigen receptor, and a method for preparing the modified immune cell. These chimeric antigens and immune cells are used for a metho...  
WO/2023/249065A1
A tissue regeneration promotion sheet (10) comprises a cell retention sheet (12), which is a non-woven fabric that contains fibers mainly composed of polycaprolactone and are capable of allowing permeation of a cell suspension containing...  

Matches 501 - 550 out of 105,148